礼来公司因减肥药需求激增 预计2026年利润超市场预期

Group 1 - The company expects its profits in 2026 to exceed Wall Street expectations, driven by a surge in demand for its obesity drugs and plans to launch an oral weight loss medication later this year [1][4] - The company's stock price rose nearly 7% in pre-market trading, attributed to the success of its blockbuster weight loss drug, Zepbound, and a shift towards self-pay models and telehealth channels in the rapidly expanding obesity market [2][5] - The company reported a diluted earnings per share of $7.54 for the quarter, surpassing analysts' expectations of $6.67 [2][5] Group 2 - The company anticipates an adjusted earnings per share of $33.50 to $35 for the year, which is higher than the analysts' average expectation of $33.23 [3][6] - The optimistic performance outlook of the company contrasts sharply with its competitor, Novo Nordisk, which has warned of significant sales declines and unprecedented pricing pressures by 2026 [2][5]